(ISSN 2638-1311)
OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Special Issue
Brain Aging and Neurodegenerative Disorders in Later Life: From Cellular Dysfunction to Novel Therapies
Submission Deadline: February 15, 2027 (Open) Submit Now
Guest Editor
Shailendra Kumar Maurya, PhD
Instructor. Department of Cellular, Molecular and Genetic Medicine, VCU School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
Research Interests: Brain metastasis; neuroinflammation; tumor microenvironment; cancer epigenetics; molecular oncology; lung and breast cancer
About This Topic
Brain aging is a complex biological process characterized by gradual structural, molecular, and functional changes that affect neuronal integrity, cognitive performance, and overall brain health. As life expectancy continues to increase worldwide, age-related neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other dementias, have emerged as major public health challenges. These disorders are driven by a combination of genetic susceptibility, environmental factors, and age-associated cellular dysfunctions that progressively impair neuronal survival and communication.
At the cellular level, brain aging is associated with mitochondrial dysfunction, oxidative stress, impaired protein homeostasis, chronic neuroinflammation, DNA damage, and dysregulated autophagy. These alterations contribute to the accumulation of toxic protein and pathogenic protein deposits found in neurodegenerative conditions. Furthermore, age-related changes in microglial and astrocytic function promote a persistent inflammatory environment that accelerates neuronal degeneration and compromises synaptic plasticity. Recent advances in neuroscience and molecular biology have significantly improved our understanding of the mechanisms underlying brain aging and neurodegenerative diseases. The identification of key molecular pathways involved in cellular senescence, proteostasis, mitochondrial quality control, and neuroimmune regulation has revealed promising therapeutic targets. Novel therapeutic strategies are currently being explored to slow disease progression, restore neuronal function, and improve quality of life in older adults. These include disease-modifying drugs targeting pathological protein accumulation, gene-editing technologies, stem cell-based regenerative therapies, neuroprotective compounds, and immunotherapies designed to enhance the clearance of toxic proteins. In addition, lifestyle interventions, including physical exercise, cognitive training, dietary modifications, and management of cardiovascular risk factors, have demonstrated significant potential in preserving cognitive health and delaying neurodegenerative processes.
Keywords
Brain; aging; neurodegeneration; cells
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
- Newsletter